Brand Name | Status | Last Update |
---|---|---|
adstiladrin | Biologic Licensing Application | 2024-10-30 |
allevia | unapproved drug other | 2025-02-27 |
as i am | C200263 | 2024-10-09 |
co-bb-52549 featuring you hydrating skin enhancing tint spf30-375 strength co-bb-52816 featuring you hydrating skin enhancing tint spf30-390 achiev... | C200263 | 2024-04-01 |
detijian nadh | unapproved drug other | 2022-02-21 |
enbrace hr | unapproved drug other | 2025-01-02 |
enlyte | unapproved drug other | 2022-07-01 |
nadolol | ANDA | 2025-06-16 |
nadolol and bendroflumethiazide | ANDA | 2016-04-15 |
numbuzin 9 nad bio super defense glow sunscreen broad spectrum spf 50 | C200263 | 2025-04-14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 1 | — | 1 |
Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | 1 | — | — | 4 |
Streptococcal infections | D013290 | EFO_1001476 | — | — | — | 3 | — | — | 3 |
Pneumococcal pneumonia | D011018 | EFO_1001474 | J13 | — | — | 1 | — | — | 1 |
Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | 1 | — | — | 1 |
Herpes simplex | D006561 | — | B00 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis b | D006509 | — | — | 1 | 1 | — | — | — | 1 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 1 | — | — | — | 1 |
Hepatitis | D006505 | — | K75.9 | 1 | 1 | — | — | — | 1 |
Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
Hepatitis c | D006526 | — | B19.2 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Bacterial infections | D001424 | — | A49 | 1 | — | — | — | — | 1 |
Toxoplasmosis | D014123 | EFO_0007517 | B58 | 1 | — | — | — | — | 1 |
Drug common name | Nadide |
INN | nadide |
Description | Nicotinamide adenine dinucleotide (NAD) is a coenzyme central to metabolism. Found in all living cells, NAD is called a dinucleotide because it consists of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine nucleobase and the other, nicotinamide. NAD exists in two forms: an oxidized and reduced form, abbreviated as NAD+ and NADH (H for hydrogen), respectively.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1 |
PDB | — |
CAS-ID | 53-84-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1234613 |
ChEBI ID | 44215 |
PubChem CID | 925 |
DrugBank | DB00157 |
UNII ID | 0U46U6E8UK (ChemIDplus, GSRS) |